No­var­tis' En­tresto in­fringes on uni­ver­si­ty patents, law­suit claims

More than a year and a half af­ter se­cur­ing FDA ap­proval for a block­buster heart drug, No­var­tis is now go­ing to court over it.

No­var­tis was served with a fed­er­al law­suit ear­li­er this week in the North­ern Dis­trict of Cal­i­for­nia, al­leg­ing that its heart fail­ure treat­ment En­tresto in­fringes a patent joint­ly held by the Uni­ver­si­ty of Michi­gan and the Uni­ver­si­ty of South Flori­da re­lat­ed to “en­gi­neer­ing crys­tals for the de­sign of new drug com­pounds.”

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER